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Poster Session I S281Methods: We reviewed the records of CMV-seropositive patients
who underwent allogenic SCT in two tertiary institutions in Singa-
pore between 2006 and 2010. The studied outcomes included CMV
reactivation, CMV disease, and 100-day mortality.
Results: 179 CMV-seropositive patients (median age 43) who un-
derwent myeloablative (N 5 78) and nonmyeloablative (N 5 101),
related (N 5 122) and unrelated (N 5 57) donor allogenic SCT
were identified. Among them, 145 (81%) had a CMV-seropositive
donor, and 34 (19%) had a CMV-seronegative donor. Median fol-
low-up time was 8.2 months. There were no significant differences
in the studied outcomes. CMV reactivation occurred in 93 (64%) pa-
tients in the CMV-seropositive donor group, and 23 (68 %) patients
in the CMV-negative donor group. CMV disease occurred in 4 (3%)
patients in the CMV-seropositive donor group and 2 (6%) in the
CMV-seronegative donor group. The 100-day mortality was 11%
in both the CMV-seronegative and CMV-seropositive donor group.
There was no statistically significant difference in 3 year disease free
survival between the two groups. A secondary aim of establishing risk
factors for CMV reactivation was performed. In multivariate analy-
sis, the use of thymoglobuline prophylaxis was observed to be the
only significant predictors for CMV reactivation. Patients receiving
thymoglobuline prophylaxis were observed to be 3.6 times more
likely to experience CMV reactivation, as compared to those who
did not receive it.
Conclusions:Our study shows that donor CMV serologic status did
not significantly affect the incidence of CMV reactivation, CMVdis-
ease, 100- day mortality, and disease free survival in CMV-seropos-
itive patients undergoing allogenic SCT. The use of thymoglobuline
prophylaxis, however, remains the most important risk factors for
CMV reactivation.351
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Background: Invasive fungal infections (IFI) remain a major cause
of morbidity and mortality in patients (pts) undergoing HCT. The
epidemiology of IFI has changed, with a higher proportion of mould
infections reported compared to earlier reports (Marr et al. Clin In-
fect Dis. 2002). The incidence of IFI in children undergoing HCT
has been reported at a range of 1.6-25%. The changes in epidemiol-
ogy of IFI are attributed to multiple factors, including corticosteroid
treatment, graft-versus-host disease (GVHD), increase in trans-
plants from alternative donors, and emergence of resistance with
use of azoles for IFI prevention. We report a low incidence of IFI
in pediatric patients treated in an arid region, using low-dose ampho-
tericin prophylaxis.
Methods:Medical records of 49 of 501 pediatric pts who had under-
gone 550 HCT procedures at our center between January 1997 and
August 2010 have been reviewed. Categorical tables were analyzed
using Pearson’s chi-square test and the Cochran-Mantel-Haenszel
test. Tabular and graphical descriptive survival analyses were per-
formed using cumulative incidence methods accounting for compet-
ing risks.
Results: Probable or proven IFI were diagnosed in 49 pts; 44 were
diagnosed within 2 years of HCT and were considered to be related
to treatment. The median age was 12.8 years (range 1-19.6 years).
Amphotericin based prophylaxis was used in 39 pts (87%) and other
agents in 5 pts (13%). Yeast and mould infections were diagnosed in
17 (2.7%) and 29 (5.2%) patients respectively. Two patients had
both yeast and mould infections. Yeast infection was bi-phasic, the
first peak (n 5 11) occurring at a median of 56 days (2-360) and
the second (n 5 6) at 400 days (365-478), post HCT, respectively.
The median day for mould infection was day +142 (10-726). HCT
modality, GVHD, steroid use, co-infection with viral or bacterial in-
fection and previous HCT were associated with IFI. The immediate
outcome of the event was resolution (n5 16, 37%), death from fun-
gal infection (n 5 12, 28%) death of disease progression (n 5 8,19%), GVHD (n 5 4, 8%) and death from other transplant related
complications (n 5 4, 8%),
Conclusion: The risk of IFI reported here appears to be lower than
historical data. This may be related to the vast use of low-dose am-
photericin formulations for prophylaxis, the arid climate, or a combi-
nation of both. A prospective study is needed to further elucidate the
role of low-dose amphotericin in prevention of IFI in HCT pts.352
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Introduction: Medical literature has established adverse clinical
outcomeswith hyperglycemia and adverse events in the inpatient set-
ting. There is a paucity of literature documenting the incidence and
subsequent effects of hyperglycemia in HSCT patients. The data in
other populations shows decreased rates of infection, morbidity and
mortality with improved glycemic control. This suggests that im-
proved glycemic control in the HSCT setting could reduce rates
of infection, GvHD, and TRM. The goal of this study is to describe
the incidence of hyperglycemia in the allo HSCT population.
Patients and Methods: A chart review was conducted on a total of
167 HCST patients up to day +100. Thirty normoglycemic, auto
HSCT recipients served as controls. The remaining 137 were allo
HSCT recipients. The primary endpoint was the incidence of hyper-
glycemia defined as one random blood glucose (BG) . 180 mg/dL.
Severe hyperglycemia was defined as BG . 250 mg/dL. Secondary
endpoints included administration of steroids, insulin, and death.
Results were analyzed utilizing Pearson’s chi squared test.
Results: Sixty patients had at least one BG from 180-250mg/dL and
68 had a BG . 250 mg/dL. The overall incidence of hyperglycemia
(. 180 mg/dL) was 76% in the study group compared to zero inci-
dence in the control group (p0.007). The majority of patients with
hyperglycemia received insulin therapy (95%). Probability of day
+100 survival was 72% if BG . 250 mg/dL, 84% for level of 180-
250 mg/dL, and 96% with levels\ 180 mg/dL. The survival rate
in the allo study group for BG\ 180 mg/dL was 96% compared
to 77% for a BG . 180 (p0.008).
Conclusions:While there is a clear increased incidence of hypergly-
cemia in the allo HSCT population, it remains unclear if this is caus-
ally related to adverse outcomes. Many factors impact survival
probability and the relationship of aggressive glucose control and
improved outcomes have yet to be examined. Further study of hyper-
glycemia, confounding variables, and aggressive insulin therapy in
a randomized, prospective manner is needed.353
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Respiratory Syncytial Virus (RSV) pneumonia leading to respira-
tory failure can be a significant cause of acute morbidity and mortal-
ity in the immuno-compromised host, with mortality rates of 70 to
100 percent being described in bone marrow transplant recipients.
High level of suspicion, availability ofmultiplex polymerase chain re-
action (PCR) technique for early detection, and immediate interven-
tion by inhaled Ribavirin may lead to improved outcome.
As a policy of our program, nasal wash samples from the transplant
recipients with respiratory symptoms are routinely sent for both
rapid antigen detection tests as well as for multiplex respiratory viral
panel PCR. We identified a total of 6 patients with RSV pneumonia
